Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Next Science Limited
  6. Summary
    NXS   AU0000041329

NEXT SCIENCE LIMITED

(NXS)
  Report
Delayed Australian Stock Exchange  -  01:59 2022-08-09 am EDT
0.9800 AUD   -1.01%
07/25NEXT SCIENCE : Investor Presentation - Q2 2022
PU
05/27Next Science CEO to Resign Before June 30, 2023
MT
05/27TRANSCRIPT : Next Science Limited - Shareholder/Analyst Call
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
0.97(c) 0.97(c) 1.01(c) 0.99(c) 0.98 Last
107 398 16 683 48 697 25 986 13 633 Volume
-6.28% 0.00% +4.12% -1.98% -1.01% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 16,4 M - -
Net income 2022 -6,06 M - -
Net cash position 2022 11,7 M - -
P/E ratio 2022 -17,6x
Yield 2022 -
Sales 2023 31,3 M - -
Net income 2023 1,44 M - -
Net cash position 2023 9,57 M - -
P/E ratio 2023 35,2x
Yield 2023 -
Capitalization 149 M 149 M -
EV / Sales 2022 8,37x
EV / Sales 2023 4,45x
Nbr of Employees -
Free-Float 51,2%
More Financials
Company
Next Science Limited is an Australia-based medical technology company. The Company's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical... 
Read more
Sector
Pharmaceuticals
Calendar
08/30Earnings Release
More about the company
Ratings of Next Science Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NEXT SCIENCE LIMITED
07/25NEXT SCIENCE : Investor Presentation - Q2 2022
PU
05/27Next Science CEO to Resign Before June 30, 2023
MT
05/27TRANSCRIPT : Next Science Limited - Shareholder/Analyst Call
CI
05/26Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer
CI
05/19Next Science Secures Australia, New Zealand Distributor for Wound Dressing Product
MT
05/18Next Science Limited Signed Multi-Year Distribution Agreement with Oraderm Pharmaceutic..
CI
05/10New Study Finds XPERIENCE™ No Rinse Solution Has Persistent Efficacy Against Both..
BU
05/10Next Science Xperience(Tm) No Rinse Solution Shows Persistent Efficacy Against Both Pla..
CI
04/28Australian Shares End Three-Day Losing Streak on Boost from Miners
MT
04/27Next Science Posts 31% Growth in Q1 Product Revenue
MT
04/27NEXT SCIENCE : Investor Presentation - Q1 2022
PU
04/21NEXT SCIENCE : 2022 Corporate Governance Statement & Appendix 4G
PU
04/21NEXT SCIENCE : 2022 agm
PU
03/21Next Science Completes Share Purchase Plan; Shares Up 3%
MT
03/21NEXT SCIENCE : Successful completion of Share Purchase Plan
PU
More news
News in other languages on NEXT SCIENCE LIMITED
05/27Le prochain PDG de Science démissionnera avant le 30 juin 2023
05/26Judith Mitchell de Next Science Limited démissionne de son poste de directeur général
05/19Next Science obtient un distributeur en Australie et en Nouvelle-Zélande pour un produi..
05/18Next Science Limited a signé un accord de distribution pluriannuel avec Oraderm Pharmac..
05/10Next Science Xperience(Tm) No Rinse Solution démontre une efficacité persistante contre..
More news
Chart NEXT SCIENCE LIMITED
Duration : Period :
Next Science Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEXT SCIENCE LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,69 $
Average target price 1,35 $
Spread / Average Target 95,1%
EPS Revisions
Managers and Directors
Judith Mitchell Chief Executive Officer, Director & MD
Jacqueline Butler Chief Financial Officer
Mark R. Compton Non-Executive Chairman
Matthew Myntti Chief Technology Officer
Jon Swanson Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NEXT SCIENCE LIMITED-20.48%149
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.51%286 307
PFIZER, INC.-16.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068